NERLYNX: The Power to Prevent Recurrence*
NERLYNX is an oral, extended adjuvant therapy, meaning it is designed to be taken after your adjuvant Herceptin® treatment (following surgery). With NERLYNX, you can help further reduce the risk that your breast cancer will return.
What is NERLYNX?
NERLYNX is a small-molecule, targeted therapy that enters and works inside the cell to permanently stop HER2 protein signals.†
People with HER2+ breast cancer have a gene that causes their cells to make too much HER2 protein:
The Benefits of NERLYNX
NERLYNX was studied in a clinical trial of 2,840 women who had early-stage HER2+ breast cancer and had undergone treatment with trastuzumab. The phase 3 trial examined the safety and effectiveness of NERLYNX by comparing women who took NERLYNX with women who were given a placebo (which did not contain the medicine in NERLYNX). Participants were selected to receive NERLYNX randomly and were not told whether they were receiving the medicine or a placebo.
In the clinical trial, NERLYNX reduced the risk of cancer returning by 34% at 2 years for all women studied with HER2+ breast cancer.‡
The clinical trial also looked at a subset of women with HER2+ breast cancer who were also hormone receptor positive (HR+) and found there was a 42% reduction in the risk of recurrence at 5 years.‡,§
By committing to NERLYNX, you can be confident in knowing you are doing everything you can to lower your risk of your cancer coming back.
*Recurrence is defined as the cancer coming back or resulting in death.
†NERLYNX targets HER2+ cancer cells, but may also affect healthy cells.
‡These are relative benefits. In absolute numbers, 94.2% of all people studied who were HER2+ and took NERLYNX had no return of cancer after 2 years, compared to the 91.9% of people on a placebo who had no return of cancer. After 5 years, 90.8% of all people studied who were HER2+ and HR+ and took NERLYNX had no return of cancer, compared to the 85.7% of people on a placebo who had no return of cancer.
§5-year data are based on an exploratory analysis of people who were HR+ and had completed a trastuzumab-based treatment 1 year or less prior to treatment with NERLYNX. Of this HER2+, HR+ population, 95% were also on endocrine therapy.
If you are considering or have started treatment, and have questions about what to expect, speak with a mentor.Connect now